Business Context and Reporting Period
This Form 8-K was filed by Neuralstem, Inc. on March 27, 2013, reporting events that occurred on March 22, 2013. The filing discloses the entry into a material definitive agreement involving a term loan and associated equity instruments. Note: The request metadata lists "Palisade Bio, Inc.", but the filing text explicitly identifies the registrant as "Neuralstem, Inc."
Key Financial Metrics and Obligations
- Loan Amount: $8.0 million term loan from Hercules Technology III, L.P.
- Net Proceeds: $7,887,958.50 (after deducting origination and legal fees).
- Interest Rate: Greater of 11.0% or 11.0% plus (Prime Rate minus 3.25%).
- Maturity Date: June 1, 2016 (or September 1, 2016 if an Additional Draw is made).
- Repayment Terms: Interest-only payments until December 1, 2013 (extendable to March 1, 2014 if Additional Draw occurs), followed by principal and interest repayment.
- Collateral: First priority liens on substantially all assets, including intellectual property.
- Equity Issuance:
- Warrant to purchase 648,808 shares at $1.0789/share.
- Advisor Shares: 259,740 common shares issued to Tripoint Global Equity, LLC.
- Advisor Warrant: To purchase 648,798 shares.
- Additional Draw: Potential for an additional $2.0 million if the company secures partnerships with upfront proceeds of at least $4.5 million.
Material Changes and Agreements
The primary material change is the execution of the Loan and Security Agreement and the Intellectual Property Security Agreement (IPSA). The company granted Hercules a first-priority security interest in its assets. The agreement includes customary covenants limiting other indebtedness, liens, acquisitions, investments, and dividends, but contains no financial covenants. Hercules holds a right to participate in future private equity placements up to $1.0 million and the right to require the company to pay up to $1.0 million of principal via common stock issuance.
Outlook, Risks, and Contingencies
- Events of Default: Include payment defaults, covenant breaches, material impairment of security interests, and bankruptcy or insolvency.
- Equity Dilution: The warrant and advisor shares/warrants introduce potential dilution. The warrant exercise price is subject to adjustment upon non-public offerings between December 22, 2012, and March 22, 2014.
- Contingent Liability: The company may be obligated to issue common stock to satisfy up to $1.0 million of principal if Hercules exercises its right.
- Advisor Compensation: The company paid $290,000 in cash plus equity instruments to the financial advisor, Tripoint Global Equity, LLC.
Investor Verification Checklist
- Verify the exact terms of the "Additional Draw" conditions to assess the likelihood of the extra $2.0 million funding.
- Review the full text of the Loan Agreement (Exhibit 10.01) for specific limitations on dividends and future debt.
- Confirm the current status of the company's intellectual property portfolio to understand the scope of the collateral pledged.
- Monitor future equity offerings between December 2012 and March 2014, as these may trigger adjustments to the warrant exercise price.
- Check subsequent filings for any exercise of the stock-for-principal option by Hercules.